Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Varalakshmi Mummidi is active in the Biotechnology & Pharmaceuticals technology area. The portfolio currently includes 1 pending office action. This single action represents the current active pursuit of patent protection in the biotech sector for the applicant.
The prosecution process is centralized, involving 1 distinct examiner and 1 distinct art unit. This concentration indicates that the technical scope of the filings falls under a single regulatory department. This simplifies the prosecution strategy by focusing on the standards of one specific art unit.
KIM, DANIELLE A is the busiest examiner, holding 1 busiest examiner pending office action. This examiner is responsible for the only active matter in the portfolio. The immediate future of the patent rights is tied to the review and decisions of this specific examiner.
Managing 1 pending office action allows for concentrated legal resources on a single matter. The direct relationship with KIM, DANIELLE A simplifies the communication strategy. This streamlined approach avoids the variability often found when dealing with multiple distinct examiners across different units.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIM, DANIELLE A | 1 | 37.1% | +56.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18023403 | POLY HYDROXY OLIGOMER COATED DOLUTEGRAVIR AQUASOMES AND METHOD THEREOF | KIM, DANIELLE A | 6d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18023403 | POLY HYDROXY OLIGOMER COATED DOLUTEGRAVIR AQUASOMES AND METHOD THEREOF | KIM, DANIELLE A | 6d |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18023403 | POLY HYDROXY OLIGOMER COATED DOLUTEGRAVIR AQUASOMES AND METHOD THEREOF | KIM, DANIELLE A | 1613 | §103§112 | Final Rejection | 6d | Pending | Feb 27, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial